Sucampo Pharmaceuticals, Inc. And Takeda Pharmaceutical Co. Ltd. Initiate Global Pivotal Phase 3 Program Of Lubiprostone In Pediatric Functional Constipation

Published: Dec 17, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals ("Takeda") today announced the initiation of a global pivotal Phase 3 clinical program of lubiprostone in pediatric functional constipation. Functional constipation is a very common gastrointestinal complaint in children and is on the rise. An analysis of longitudinal data in the United States showed a nearly 4-fold increase in rates of constipation over the last decade.

Help employers find you! Check out all the jobs and post your resume.

Back to news